Early effective treatment strategies can have a significant impact on long-term effects for patients with MDD.
Mona Chitre, PharmD, CGP: Because MDD [major depressive disorder] is a symptomatic disease with such an impact on quality of life, the goal is to have early, effective treatment as quickly as possible. That enables the patient to feel improvement from the condition and supports treatment adherence. Treatment is often customized and specific for the patient, but if we can have early, effective treatment, there’s a whole host of downstream improvements around overall improvement of health that our members will benefit from. That’s always a goal in treating this condition.
Jay Weaver, PharmD, MPH: One of the main contributors to outcomes is how quickly we begin to see a response in someone. As we talked about before, these medications have a downstream effect on neurotransmitters both up- and downregulating different parts of that process. It can take time to achieve. During that time, as the time wears on and people aren’t getting relief, they begin to withdraw more. They’re less committed to care. We lose them to follow-up. There are all sorts of things that happen over that time, so a key contributor is finding the effective therapy fast or, if it’s not going to work, moving them quickly onto another therapy that could work for them. For a multitude of reasons, that’s the key driver to be able to move forward with these therapies.
Transcript edited for clarity.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More